These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 33248325)
21. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus. Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382 [TBL] [Abstract][Full Text] [Related]
22. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956 [TBL] [Abstract][Full Text] [Related]
23. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. Rivas-Estilla AM; Svitkin Y; Lopez Lastra M; Hatzoglou M; Sherker A; Koromilas AE J Virol; 2002 Nov; 76(21):10637-53. PubMed ID: 12368306 [TBL] [Abstract][Full Text] [Related]
24. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation. Panigrahi R; Hazari S; Chandra S; Chandra PK; Datta S; Kurt R; Cameron CE; Huang Z; Zhang H; Garry RF; Balart LA; Dash S PLoS One; 2013; 8(8):e72791. PubMed ID: 24009705 [TBL] [Abstract][Full Text] [Related]
25. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. Kanda T; Yokosuka O; Imazeki F; Tanaka M; Shino Y; Shimada H; Tomonaga T; Nomura F; Nagao K; Ochiai T; Saisho H J Viral Hepat; 2004 Nov; 11(6):479-87. PubMed ID: 15500548 [TBL] [Abstract][Full Text] [Related]
27. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Noguchi T; Satoh S; Noshi T; Hatada E; Fukuda R; Kawai A; Ikeda S; Hijikata M; Shimotohno K Microbiol Immunol; 2001; 45(12):829-40. PubMed ID: 11838900 [TBL] [Abstract][Full Text] [Related]
28. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Zhu H; Zhao H; Collins CD; Eckenrode SE; Run Q; McIndoe RA; Crawford JM; Nelson DR; She JX; Liu C Hepatology; 2003 May; 37(5):1180-8. PubMed ID: 12717400 [TBL] [Abstract][Full Text] [Related]
29. Diversity of the hepatitis C virus NS5B gene during HIV co-infection. Ngwaga T; Kong L; Lin D; Schoborg C; Taylor LE; Mayer KH; Klein RS; Celentano DD; Sobel JD; Jamieson DJ; King CC; Tavis JE; Blackard JT PLoS One; 2020; 15(8):e0237162. PubMed ID: 32750098 [TBL] [Abstract][Full Text] [Related]
31. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Pflugheber J; Fredericksen B; Sumpter R; Wang C; Ware F; Sodora DL; Gale M Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4650-5. PubMed ID: 11904369 [TBL] [Abstract][Full Text] [Related]
32. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. Taylor DR; Puig M; Darnell ME; Mihalik K; Feinstone SM J Virol; 2005 May; 79(10):6291-8. PubMed ID: 15858013 [TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Klepper A; Eng FJ; Doyle EH; El-Shamy A; Rahman AH; Fiel MI; Avino GC; Lee M; Ye F; Roayaie S; Bansal MB; MacDonald MR; Schiano TD; Branch AD Hepatology; 2017 Aug; 66(2):357-370. PubMed ID: 27642141 [TBL] [Abstract][Full Text] [Related]
34. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Gu Z; Graci JD; Lahser FC; Breslin JJ; Jung SP; Crona JH; McMonagle P; Xia E; Liu S; Karp G; Zhu J; Huang S; Nomeir A; Weetall M; Almstead NG; Peltz SW; Tong X; Ralston R; Colacino JM Antimicrob Agents Chemother; 2013 Jul; 57(7):3250-61. PubMed ID: 23629699 [TBL] [Abstract][Full Text] [Related]
35. Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway. Liu WL; Yang HC; Su WC; Wang CC; Chen HL; Wang HY; Huang WH; Chen DS; Lai MY PLoS One; 2012; 7(9):e43824. PubMed ID: 22962590 [TBL] [Abstract][Full Text] [Related]
36. Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection. Watanabe T; Sakamoto N; Nakagawa M; Kakinuma S; Itsui Y; Nishimura-Sakurai Y; Ueyama M; Funaoka Y; Kitazume A; Nitta S; Kiyohashi K; Murakawa M; Azuma S; Tsuchiya K; Oooka S; Watanabe M Antimicrob Agents Chemother; 2011 Jun; 55(6):2537-45. PubMed ID: 21444704 [TBL] [Abstract][Full Text] [Related]
37. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. Paul D; Hoppe S; Saher G; Krijnse-Locker J; Bartenschlager R J Virol; 2013 Oct; 87(19):10612-27. PubMed ID: 23885072 [TBL] [Abstract][Full Text] [Related]
38. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Erickson AK; Seiwert S; Gale M Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919 [TBL] [Abstract][Full Text] [Related]
40. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness. Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]